Clinical assessment of Alzheimer's disease
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) was established in 1986 to develop standardized methods to evaluate persons with Alzheimer's disease (AD) and gather clinical, neuropsychological, and neuropathologic information about this illness. CERAD clinical battery. The clinical assessment protocol(table 1) was designed to provide clinicians with the minimum information necessary to make a confident diagnosis of AD.1 The battery includes reliable and validated measures or those of time-honored value. Information is obtained through semistructured interviews with the patient and an informant, a general physical and neurologic examination of the patient, and brief cognitive scales. Questions are asked regarding prior illnesses and injuries and symptoms of depression. Other questions cover the history of possible symptoms of dementia, medications that might contribute to such symptoms, and duration of the dementing process. We administer a modified Blessed Rating Scale for Dementia2 to determine informant-reported changes in instrumental and basic activities of daily living and the Short Blessed Test3 to measure orientation, memory, and concentration. We evaluate the patient's language, calculation, and visuospatial performance. Laboratory studies include a routine hemogram and biochemical screen, thyroid function test, and vitamin B-12 level. Neuroimaging of the brain by either CT or MRI is required. A protocol for obtaining and reading neuroimages has been developed.4 Global severity of dementia is staged in accordance with the Clinical Dementia Rating (CDR) scale.5(With evaluation of the cases until death, the stages assessed by the CDR have been validated and expanded to include profound [coded as 4] and terminal[coded as 5].)6 Diagnostic criteria for AD are those proposed by the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association(NINCDS/ADRDA)7 modified to require memory loss of at least 12 months' duration (instead of 6 months), and …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Morris, J. C., Edland, S., Clark, C., Galasko, D., Koss, E., Mohs, R., van Belle, G., Fillenbaum, G., & Heyman, A. (1993) · Neurology · doi:10.1212/wnl.43.12.2457 · Cited by 441
Self-citationAssessment [RETIRED]: Magnetoencephalography (MEG)
(1992) · Neurology · doi:10.1212/wnl.42.1.1 · Cited by 232
Cited by
Is the underlying cause of epilepsy a major prognostic factor for recurrence?
Semah, F., Picot, M.-C., Adam, C., Broglin, D., Arzimanoglou, A., Bazin, B., Cavalcanti, D., & Baulac, M. (1998) · Neurology · doi:10.1212/wnl.51.5.1256 · Cited by 1,113
Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease
Jack, C. R., Petersen, R. C., Xu, Y., O'Brien, P. C., Smith, G. E., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1998) · Neurology · doi:10.1212/wnl.51.4.993 · Cited by 666
Verghese, P. B., Castellano, J. M., Garai, K., Wang, Y., Jiang, H., Shah, A., Bu, G., Frieden, C., & Holtzman, D. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220484110 · Cited by 556
Quadri, P., Fragiacomo, C., Pezzati, R., Zanda, E., Forloni, G., Tettamanti, M., & Lucca, U. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.1.114 · Cited by 339
Clinical relevance of the neurotrophins and their receptors
Allen, S. J., & Dawbarn, D. (2006) · Clinical Science · doi:10.1042/cs20050161 · Cited by 320
Metadata
- Authors
- Morris, J. C.
- Venue
- Neurology
- Published
- 1997-09
- Volume
- 49
- Issue
- 3_suppl_3
- Pages
- S7-10
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2036314477
- Cited by
- 41
- References
- 2
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical assessment of Alzheimer's disease. https://app.cochat.ai/papers/10.1212/wnl.49.3_suppl_3.s7
- The paper
- Morris, J. C. (1997). Clinical assessment of Alzheimer's disease. Neurology. https://doi.org/10.1212/wnl.49.3_suppl_3.s7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.